Interest of the SPECT-CT Scan SUVspect in the New Generation of

Status Recruiting

Clinical Trial Summary

Since 2017, a revolution began in the departments of nuclear medicine, with the routine use of gamma-cameras with semiconductor. These gamma-cameras (which obtained the CE-marking in 2016), offer a technological breakthrough by providing an additional information. They allow "to quantify" for the 1st time in clinical routine conditions, the quantity of radioactivity, by means of a "SUVspect", in a volume of interest, while respecting the recommendations of best practice of the learned societies of French nuclear medicine (SFMN), European (EANM) and American (SNM), without injection of tracer nor acquisition or additional irradiation. The SUVspect is therefore an indicator of the quantity of tracer in a given volume of acquisition. Until now, the interpretation criteria of scintigraphies are based on the homogeneity of distribution of a tracer in the explored organ (for single organs such as the heart or the thyroid, for example) or in the asymmetry of distribution of the tracer (for the double organs, such as the kidney or the joints). This new gamma-camera allows to study the distribution of the radio-tracers in "list" mode, allowing to retrospectively reconstruct the images in various ways (for example, by modifying the size of the matrix of acquisition, the energy windows, the time of acquisition). Therefore, we can simulate and propose modifications in current procedures. Every patient referred to our department of nuclear medicine to undergo a scintigraphy with a tracer of nuclear medicine (with a marketing authorization) can, while benefiting from an examination by this gamma-camera, to be the object of this study, and to profit from this additional information. So, without changing the diagnosis or the usual care, we wish to take advantage of this additional information to improve the criteria of interpretation of our examinations. This possibility being new, there is no available bibliography (our department is the 5th department of nuclear medicine in Europe to equip itself with this large field-of-view gamma-camera CZT, the DNM 670, made by General Electric), while 2961 articles speak about the SUVmax (in PET) in Pubmed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03414021
Study type	Observational
Source	Lille Catholic University
Contact	Marie Paule Lebitasy, MD
Phone	03 20 22 57 41
Email	Lebitasy.Marie-Paule@ghicl.net
Status	Recruiting
Phase
Start date	January 31, 2018
Completion date	December 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04624412` - Different Intensities of Continuous Aerobic Exercises in Cardiac Rehab Phase 2	N/A
Completed	`NCT05563701` - Evaluation of the LVivo Image Quality Scoring (IQS)
Recruiting	`NCT04561908` - Transcatheter Microguidewire Drilling for Transseptal Left Atrial Access	N/A
Active, not recruiting	`NCT06190743` - Perception of Cardiovascular Risk
Completed	`NCT04580095` - Artificial Intelligence for Improved Echocardiography	N/A
Completed	`NCT04562636` - Evaluating a Messaging Campaign in the United States	N/A
Recruiting	`NCT03277365` - MyGeneRank: A Digital Platform for Next-Generation Genetic Studies	N/A
Active, not recruiting	`NCT05553106` - Evaluation of Cognitive Status, Kinesiophobia, Physical Activity Level, and Functional Performance in Coronary Intensive Care
Completed	`NCT03429920` - Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors	N/A
Recruiting	`NCT04390672` - Multivessel TALENT	N/A
Enrolling by invitation	`NCT03314818` - Natural History of Carotid Plaque as Determined by 3D Ultrasound	N/A
Withdrawn	`NCT03289104` - Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX	N/A
Completed	`NCT02917213` - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
Completed	`NCT02046902` - Developing and Testing a Personalized Evidence-based Shared Decision-making Tool for Stent Selection
Completed	`NCT01944254` - The Precision of Pulmonary Artery Cardiac Output-measurements in Spontaneously Breathing Patients	N/A
Completed	`NCT01909349` - Web-based Aftercare Intervention for Cardiac Patients	N/A
Recruiting	`NCT01457586` - Hemoderivative Imputable Complications in Initial Uncomplicated Heart Surgery	Phase 4
Recruiting	`NCT01541163` - Heart and Ischemic STrOke Relationship studY	N/A
Recruiting	`NCT01207167` - Mediators of Atherosclerosis in South Asians Living in America
Terminated	`NCT00968383` - Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Interest of the SPECT-CT Scan SUVspect in the New Generation of Gamma-cameras With Semiconductor — GAMMA-CAM

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms